Lamar Advertising Free cash flow decreased by 45.2% to $114.25M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.8%, from $97.86M to $114.25M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 2.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $176.86M | $172.88M | $191.61M | $73.28M | $163.55M | $183.47M | $194.24M | $66.43M | $147.44M | $183.40M | $208.07M | $81.08M | $233.69M | $197.25M | $236.30M | $97.86M | $191.29M | $185.81M | $208.30M | $114.25M |
| QoQ Change | — | -2.2% | +10.8% | -61.8% | +123.2% | +12.2% | +5.9% | -65.8% | +122.0% | +24.4% | +13.5% | -61.0% | +188.2% | -15.6% | +19.8% | -58.6% | +95.5% | -2.9% | +12.1% | -45.2% |
| YoY Change | — | — | — | — | -7.5% | +6.1% | +1.4% | -9.4% | -9.9% | -0.0% | +7.1% | +22.1% | +58.5% | +7.6% | +13.6% | +20.7% | -18.1% | -5.8% | -11.8% | +16.8% |